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Unresectable stage III represents nearly one-third of all NSCLC
cases. Until a few years ago, standard treatment consisted of once
daily fractionation thoracic high-dose radiotherapy. With this form
of treatment, median survival was less than 1 year and 5-year
survival rate nearly 5%, due to frequent systemic and local failures
(Perez et al, 1987). However, more recent evidence has accumu-
lated indicating that chemotherapy added to radiotherapy can
increase long-term survival (Non-small Cell Lung Cancer
Collaborative Group, 1995), and randomized studies comparing
sequential chemoradiation to radiotherapy alone have consistently
reported a better outcome in favour of the combined modality
treatment. Among these studies, the Cancer and Leukemia Group
B (CALGB), which has compared two courses of cisplatin–
vinblastine induction chemotherapy followed by standard thoracic
irradiation to irradiation alone, has reported a nearly 10% differ-
ence in actuarial survival in favour of combined modality which
was maintained through 7 years of follow-up (Dillman et al,
1996). This result has been corroborated by a confirmatory study
conducted by the Radiation Therapy Oncology Group (RTOG)
and the Eastern Cooperative Oncology Group (ECOG) (Sause et
al, 1995).
An alternative method of integrating chemotherapy and radio-
therapy is to deliver these two treatment modalities concurrently,
in order to take also advantage of possible radiosensitizing proper-
ties of some chemotherapeutic agents. Among these agents,
cisplatin has been the most extensively used, due to a laboratory
evidence of strong radiopotentiating activity (Dewitt, 1987). A
series of randomized studies have assessed the role of low-dose
cisplatin combined with radiotherapy, as compared to radiotherapy
alone. One of these studies, which was conducted by the European
Organisation for Research and Treatment of Cancer (EORTC),
reported a statistically significant benefit for this type of concomi-
tant chemoradiation treatment (Schaake-Koning et al, 1992).
Interestingly, while the benefit of chemotherapy used as an induc-
tion to radiotherapy can be mainly attributed to an effect on
systemic disease (Le Chevalier et al, 1991; Crinò et al, 1993),
cisplatin used concurrently with radiotherapy appears to improve
essentially local control (Soresi et al, 1988; Schaake-Koning et al,
1992). This observation provides the rationale for combining the
two modalities of integrating chemotherapy and radiotherapy
(induction chemotherapy followed by concurrent chemoradiation)
aimed at associating the benefits of an improved control on loco-
regional disease and on micrometastases. The present study was
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designed to test this hypothesis and to verify the activity and
feasibility of a novel chemoradiation programme, derived from
a combination of CALGB (Dillman et al, 1996) and EORTC
(Schaake-Koning et al, 1992) study best arms, consisting of
induction chemotherapy followed by standard radiotherapy and
simultaneous daily low-dose cisplatin.
PATIENTS AND METHODS
Eligibility
Eligibility criteria for this trial included a cytological or histo-
logical diagnosis of NSCLC, clinical stage IIIA/B disease judged
unresectable by a thoracic surgeon (GBR) and presence of measur-
able or evaluable disease according to World Health Organization
(WHO) criteria. Patients were required to have a WHO perfor-
mance status equal or less than 2, to be no more than 70 years old
and to have a weight loss less than 10% of total body weight in the
preceding 6 months. At the time of study entry, eligible patients
were required to have haemoglobin greater than 10 g dl–1,
WBC count higher than 4000 ml–1, a platelet count higher than 100
000 ml–1, bilirubin less than 2.5 mg dl–1 and creatinine less than 1.5
mg dl–1. Eligibility for this trial included also the presence of a
forced expiratory volume in 1 s (FEV1) higher than 1 l. No
previous chemotherapy or radiotherapy was allowed.
Patients were excluded from study participation if they had any
of the following conditions: malignant pleural effusion or involve-
ment of supraclavicular lymph nodes, any concomitant serious
illness, infectious disease in the previous 3 weeks, life-expectancy
less than 6 months, stage I–II disease, superior vena cava
syndrome, post-obstructive pneumonia, life-threatening haemo-
ptysis, small-cell lung cancer component in the biopsy specimen,
myocardial infarction in the previous 6 months, clinical evidence
of cardiac failure and/or uncontrolled arrhythmia. Patients with
previous or current malignancies at other sites, with the exception
of in situ carcinoma of the cervix uteri and/or basal cell carcinoma
of the skin were also excluded.
Pretreatment evaluation included a complete medical history
and physical examination with neurologic evaluation, chest X-ray
and computerized tomography (CT) scan, abdominal CT scan or
ultrasonography, fiberoptic bronchoscopy, pulmonary function
tests, audiograms, blood chemistry including complete blood cell
counts, electrolytes, blood urea nitrogen, serum creatinine, liver
function tests, serum tumour markers (CEA, CYFRA, NSE),
urinalysis and ECG.
Treatment
The entire treatment was delivered on an outpatient basis.
Induction chemotherapy included vinblastine 5 mg m–2 given as an
intravenous (i.v.) bolus on days 1, 8, 15, 22 and 29, and cisplatin
100 mg m–2 given i.v. over a 30- to 60-min period on days 1 and 22
along with 2 litres NS hydration and forced diuresis.
Continuous thoracic irradiation with concurrent cisplatin started
from day 43. Cisplatin was administered bolus at a 5 mg m–2 daily
dose, 1–2 h before each radiotherapy administration. Patients were
required to have an oral intake of at least 2 l of fluids daily.
Radiotherapy was delivered with high energy photon beams from
a 15–18 MeV linear accelerator. The total dose delivered was
60 Gy in 30 fractions, 5 fractions per week (Monday to Friday).
Target volume included the prechemotherapy primary tumour with
2-cm margins, ipsilateral hilum and mediastinum from the sternal
notch to 5 cm below the carina. Ipsilateral supraclavicular nodes
were included for upper lobe primary tumours or when high
mediastinal lymph nodes (stations 1 and 2) were involved. Inferior
mediastinal nodes were treated in case of lower lobe tumours.
When left upper lobe was the site of the neoplasm, contralateral
supraclavicular nodes were included in the target volume. Two
opposite antero-posterior fields were employed for the first
22–24 fractions.
After the first 44–48 Gy were delivered, the field was reduced
to include only the primary tumour and gross lymph node volume
with 1-cm margin for an additional 12–16 Gy. This latter treatment
was realized with 2–3 computer planned fields avoiding the spinal
cord (where the maximum dose should not exceed 48 Gy). All
patients were submitted to CT simulation and volumes were drawn
on CT images. Customized blocks were defined with beams-
eye-view support. Dose distribution calculation was performed
employing several CT images using 2D multiple slices treatment
planning system. Normalization and weighing points were identi-
fied with isocentre dose and homogeneity according to ICRU
recommendation (International Commission on Radiation Units
and Measurements, 1993).
Dose modifications
The use of haemopoietic growth factors was not allowed. Dose
modifications were planned according to toxicity. Cisplatin dose,
during induction chemotherapy, had to be reduced of 25% if the
preceding course had produced grade IV leukopenia and/or
thrombocytopenia. If myelosuppression precluded the starting of
the second chemotherapy cycle on day 22, the treatment was post-
poned for 1 week or to complete resolution of toxicity. Vinblastine
dosing was omitted in case of grade III–IV haematological
toxicity. Chemoradiation could be interrupted for periods up to
10 treatment days for grade ³ III oesophageal toxicity and for
grade IV haematological toxicity.
Follow-up
Blood count and serum creatinine were obtained weekly during
treatment. Following completion of radiation therapy, patients
were seen at 4-week intervals for 6 months, then at 8-week
intervals for 6 months, then every 3 months for 2 years and every
6 months thereafter. Follow-up evaluation included: a complete
medical history and physical examination with neurologic evalua-
tion, blood chemistry including complete blood cell counts,
electrolytes, blood urea nitrogen, serum creatinine, liver function
tests, serum tumour markers (CEA, CYFRA, NSE), urinalysis,
chest CT scan and abdominal CT scan or ultrasonography at 3 and
6 months after completion of treatment and every 6 months there-
after. A fiberoptic bronchoscopy was obtained within 3 months
from the end of treatment in responding patients and every year
thereafter. Pulmonary function tests and audiograms were repeated
only once after completion of treatment. Patients have been
evaluated for tumour response based on CT scan at 2–3 months
from radiotherapy termination. More sophisticated work-up was
performed only if indicated.
Complete response (CR) was defined as complete disappear-
ance of all signs of disease on CT or the presence of minimal CT
abnormalities attributable to radiation fibrosis which did not
change in subsequent CT scans. Definition of CR required a312 A Ardizzoni et al
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negative fiberoptic bronchoscopy with biopsy. A partial response
(PR) was a reduction of 50% or more in the sum of product of the
longest perpendicular diameters of the tumour, measured with CT
scan carried out at 2–3 months from the end of treatment. Stable
disease (SD) was indicated by a less than 50% reduction or less
than 25% increase in tumour size. Early death was defined as a
death occurring before response evaluation. All CT scans were
reviewed by a committee including one radiologist (MC), two
oncologists (AA, FG), one radiotherapist (TS) and one chest
physician (CM). All members of the committee had to agree about
the judgment on response. Patients who progressed after radio-
therapy were offered a second-line treatment or best supportive
care only. No surgery was planned after the chemoradiation
programme. Chemotherapy and chemoradiation toxicities were
evaluated according to WHO criteria (WHO, 1979).
Study design and statistical analysis
This study was designed as a prospective, single-institution, non-
randomized phase II trial. The trial was conducted under the
auspices of the EORTC Lung Cancer Cooperative Group who
significantly contributed to the design of the study.
The primary aim of the study was to assess the activity and the
toxicity of induction chemotherapy followed by radiotherapy
combined with daily cisplatin in unresectable stage III NSCLC
patients who had not received any prior chemo- and/or radio-
therapy. The main end point was response rate.
To calculate the sample size we adopted Simon’s minmax two-
stage design for phase II clinical trials which minimizes the
expected number of patients to be accrued if a combination has
low activity (Simon, 1989).
At the time of the study planning, a regimen with a response rate
of 50% in this population of patients was considered worthy of
further study. The sample size was calculated on the following
assumptions: alpha and beta errors were both set at 10% while P0
and P1, defined according to Simon (1989), were set at 30% and
50% respectively. In the first stage, 28 patients had to be enrolled.
If ≤ 7 responses were observed, the accrual had to be stopped and
the treatment protocol rejected. In the case of > 7 responses,
11 more patients had to be accrued. The treatment regimen had to
be accepted if ³ 16 responses out of 39 evaluable patients were
observed.
All accrued patients were included in the final analysis of
response rate and survival on an ‘intention to treat’ principle,
thereby including also early deaths, early progressions and
protocol violations. Overall survival (OS) was computed as the
time from start of treatment to death or last visit. Event-free
survival (EFS) was computed as the time from start of treatment to
relapse at any site, death, or last visit. Estimates of OS and EFS
were calculated according to the Kaplan–Meier product-limit
method (Peto et al, 1977). Follow-up times were truncated on 28
February, 1998. The protocol was approved by the local Ethical
Committee and Institutional Review Board. An informed consent
was obtained from all registered patients.
RESULTS
Patient characteristics
A total of 32 patients were accrued into the study from June 1993
to July 1997. The accrual was terminated earlier, as soon as we
reached the number of objective responses required by the statis-
tical design to consider the regimen worthy of further testing. All
patients, except one, were males; the median age was 60.5 (range
44–70 years). Seventeen patients (53%) had WHO performance
status (PS) 0, 15 patients (47%) had PS 1. Histology consisted of
adenocarcinoma in ten (31%) patients and squamous cell carci-
noma in 22 (69%) patients. Ten (31%) patients had clinical stage
IIIA disease and 22 (69%) had stage IIIB disease. The characteris-
tics of the 32 patients are listed in Table 1.
Activity
As shown in Table 2, 18 of 32 patients (56%, 95% confidence
interval (CI) 38–73%) had a major response (11 PR, seven CR).
Five patients died before response evaluation (three of early
progression, one of pulmonary toxicity and one of cardiac infarc-
tion); seven patients were classified as progressive and one as
stable at the time of response assessment. One patient was
excluded from analysis because he underwent resection before
completion of chemoradiation.
Most relapses or progression occurred locally. The first sites of
initial disease progression are listed in Table 3. As of 28 February
1998, six of seven patients with CR and one of 11 patients with PR
remain alive with no recurrence or progression of disease at 7, 27,
37, 38, 49, 54 and 56 months respectively.
Table 1 Patient characteristics
Characteristic No. of patients (%)
(n = 32)
Male/female 31/1
Age (years)
Range 44–70
Median 60.5
PS
0 17 (53)
1 15 (47)
Cell type
Adenocarcinoma 10 (31)
Squamous cell 22 (69)
Clinical Stage
IIIA 10 (37)
T1–2N2 4
T3N2 6
IIIB 22 (63)
T1–3N3 7
T4N0–2 13
T4N3 2
Table 2 Maximum tumour response after the end of treatment
Response Number of patients (%)
(n = 32)
Complete response 7 (22%)
Partial response 11 (34%)
Stable disease 1 (3%)
Early death 5 (16%)
Disease progression 7 (22%)
Dropouts 1 (3%)Phase II study of concurrent chemoradiation in NSCLC 313
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Toxicity
Thirty-two patients were evaluable for induction chemotherapy
toxicity. Grade III–IV leukopenia was observed in 10/32 (31%)
cases, grade II anaemia in 5/32 (16%) and grade IV thrombo-
cytopenia in only one case (3%). Non-haematological toxicity
consisted mainly of grade I paraesthesia which occurred in 5/32
patients (16%).
Twenty-eight patients were evaluable for chemoradiotherapy
plus daily cisplatin toxicity. Four patients could not be evaluated
for radiotherapy toxicity because of early progressive disease
or death before starting irradiation. Haematological toxicity
consisted of grade III leukopenia observed in 6/28 patients (21%),
grade III anaemia in 2/28 (7%) and grade III thrombocytopenia in
2/28 (7%) patients respectively. Oesophagitis, although frequent
(22/28), was severe in only two patients. Only one case of radia-
tion pneumonitis was observed. No lung function tests impairment
was detected at completion of treatment. Four cases of tinnitus
were seen. No objective neurological deficit, attributable to
peripheral neurotoxicity, could be documented. No cumulative
> grade I renal toxicity was observed. One treatment-related death
due to respiratory failure was observed in the only patient who
developed radiation pneumonitis (Table 4).
Chemotherapy and chemoradiotherapy delivered
Chemoradiation, including daily cisplatin and thoracic irradiation,
was completed as planned by the protocol in all patients who
began the treatment. Some patients had brief delays (less than 1
week) due to toxicity or technical reasons. Mean projected/
planned dose % of cisplatin and vinblastine during induction
chemotherapy were 95% and 85% respectively. The main reason
for reduced dose intensity of vinblastine was the omission of day 8
or 15 dosing, due to haematological toxicity. During induction
chemotherapy, there was a treatment delay in ten patients, a
cisplatin dose reduction in two and a vinblastine dose reduction in
17 due to toxicity, primarily myelosuppression.
Survival
All 32 patients enrolled into the trial were included in the survival
analyses. The median follow-up was 38.4 (range 7.5–56) months.
Twenty-five patients have died. Seven patients were surviving
without evidence of recurrence or progression at the last follow-up
and six of them were disease-free after a minimum follow-up
of 2 years. The median overall survival was 12.5 months. The
actuarial survival at 1, 2 and 3 years was 52%, 26% and 19%
respectively (Figure 1). The median event free survival was
8.3 months with a probability of 40%, 23% and 20% at 1, 2 and
3 years respectively.
DISCUSSION
Currently, the combination of chemotherapy and radiotherapy
represents the standard treatment of locally advanced unresectable
NSCLC (American Society of Clinical Oncology, 1997). How-
ever, the best timing of combining the two treatment modalities
remains uncertain. The sequential approach, with chemotherapy
preceding irradiation, has been the most extensively used in the
trials performed to demonstrate superiority of combined modality
treatment over radiotherapy alone. In addition, it has little additive
toxicity and no technical problems. Improved results of sequential
chemo-irradiation over radiotherapy alone are supposed to derive
mainly from the effect of induction chemotherapy on micro-
metastatic disease (Le Chevalier et al, 1991; Crinò et al, 1993). As
to the concurrent use of chemotherapy and irradiation, although
the number of randomized studies in which this modality has been
compared to radiotherapy alone is small, most of these trials have
also been positive (Jeremic et al, 1996), including those where
Table 3 Sites of initial disease progression
Variable Number of patients (%)
(n = 20)
Distant alone 4 (20)
Local alone 14 (70)
Distant+local 1 (5)
Unknown 1 (5)
Table 4 Chemotherapy and chemoradiation toxicity
Toxicity Grade Chemotherapy Chemoradiation
No. of patients (%) No. of patients (%)
(n = 32) (n = 28)
Anaemia I 8 (25) 4 (14.3)
II 5 (15.6) 6 (21.4)
III 0 2 (7.1)
Leukopenia I 6 (18.7) 7 (25)
II 13 (40.6) 7 (25)
III 5 (15.6) 6 (21.4)
IV 5 (15.6) 0
Thrombocytopenia I 2 (6.2) 2 (7.1)
II 1 (3.1) 3 (10.7)
III 0 2 (7.1)
IV 1 (3.1) 0
Stomatitis I 2 (6.2) 19 (67.8)
Oesophagitis II 2 (6.2) 1 (3.5)
III 1 (3.1) 2 (7.1)
Nausea/vomiting I 12 (37.5) 10 (35.7)
II 1 (3.1) 0
Asthenia I 9 (28.1) 2 (7.1)
Paraesthesias I 5 (15.6) 3 (10.7)
Tinnitus II 3 (9.3) 1 (3.5)
Creatinine I 4 (12.5) 2 (7.1)
Pulmonary toxicity I 0 1 (3.5)
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chemotherapy consisted of single agent cisplatin (Schake-Koning
et al, 1992). This type of combined modality treatment appears to
exert its action mainly by improving local control, probably as a
result of a radiopotentiating effect of chemotherapy. However,
with the exception of those regimens where concurrent chemo-
therapy consisted of single-agent cisplatin, most regimens using
combination chemotherapy or third-generation agents concur-
rently with thoracic irradiation have shown severe additive toxi-
city, particularly oesophagitis and pneumonitis (Lee et al, 1996;
Reckzeh et al, 1996; Frasci et al, 1997). Recently, there have been
a number of attempts to further improve the results of combined
chemoradiation by using more recently developed chemotherapy
regimens and by adding sequential chemotherapy to concurrent
chemoradiation in order to take possible advantage of two
different chemoradiation strategies combined together (Greco et
al, 1996; Choy et al, 1997; Isokangas et al, 1998). Although
preliminary results have been extremely promising in terms of
activity, the enhanced normal-tissue toxicity resulting from these
novel chemoradiation regimens is worrying.
In the present study, we have attempted to combine sequential
and concurrent chemoradiation without incurring in prohibitive
toxicities, by integrating two well known regimens, both proved
highly feasible and superior to radiotherapy alone. The sequential
part of our regimen was that of the CALGB study number 8433
(Dillman et al, 1996), while the concurrent part was derived from
the EORTC study number 08844 (Schaake-Koning et al, 1992),
with the exception that radiotherapy was continuous as opposed to
split-course, and, consequently, the dose of cisplatin reduced, as
previously piloted by the Southwest Oncology Group (SWOG)
(Hazuka et al, 1994).
The activity of our regimen seems promising. The accrual was
terminated earlier as we met the end point of the study (16 objec-
tive responses). Median survival was 12.5 months and 1-, 2-
and 3-year actuarial survival rate were 52%, 26% and 19%
respectively. Although this was a phase II study with a relatively
small number of patients accrued in a long period of time, our
survival data compare favourably with those of CALGB and
EORTC trials. In these studies, corresponding figures were 54%,
26% and 24% survival at 1, 2 and 3 years respectively in the
CALGB study and 54%, 26% and 16% in the EORTC study.
In view of the lower toxicity of our chemoradiation programme,
the results obtained in this study compare favourably also with
those of more recent combined modality regimens. In fact,
oesophagitis, although common, was severe requiring tube feeding
in only two cases. In contrast, incidence of severe oesophagitis in
most recently developed concurrent chemoradiation programmes
was reported as high as 45% (Greco et al, 1996). In addition, radi-
ation pneumonitis, which has been reported as one of the most
serious complications with the concurrent use of chemotherapy
and radiation (Reckzeh et al, 1996) was almost absent in our study.
Most of our patients underwent serial pulmonary function tests to
assess possible subclinical pulmonary damage. Significant
changes of these tests have never been observed. At the beginning
of our study, we were concerned of possible cumulative neurolog-
ical and auditory cisplatin toxicity. In fact, the projected cumula-
tive cisplatin dose of our regimen was 350 mg m–2. For this reason,
serial audiometric tests and clinical neurological examinations
were planned. No objective loss of neurologic or auditory function
was observed in any of our patients.
The most important toxicity of our regimen was myelosuppres-
sion during induction chemotherapy. The combination of cisplatin
and vinblastine was chosen as induction chemotherapy for our
programme in order to be consistent with the CALGB regimen
from which our chemoradiation programme was derived.
However, the use of this regimen is no longer justified at the
present time given the availability of less toxic and more active
last generation chemotherapy regimens (Giaccone et al, 1998).
In conclusion, we believe that our chemoradiation programme,
as described in this report, is promising in terms of anti-tumour
activity and long-term survival, highly feasible in terms of
practicality and devoid of significant additive pulmonary and
oesophageal toxicity and of cumulative cisplatin toxicity.
Therefore, further studies with this combined modality approach
are justified. Exploring the possible superiority of sequential plus
concurrent chemoradiation over either single combined modality
treatment is, in our opinion, one of the research priorities in the
field of multimodality therapy of locally advanced NSCLC. In
this respect, our regimen can be considered as an alternative to
more toxic and expensive integrated regimens.
Despite the effort to improve local control by adding chemo-
therapy to radical radiotherapy in a concurrent and sequential
fashion, thoracic progression still represents a major reason of
failure. New strategies to further improve local control, such as the
addition of post-treatment radical surgery (Eberhardt et al, 1998)
or the use of hyperfractionated radiotherapy (Choy et al, 1997;
Frasci et al, 1997) should also be pursued.
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